SGLT-2 inhibitor use in the management of glucose in type 2 diabetes could reduce blood pressure in patients with hypertension….
In a new study, researchers found that empagliflozin lowered blood pressure in patients with type 2 diabetes and hypertension. Hypertension affects about two-thirds of patients with diabetes.
See more SGLT-2 Resources
The primary outcome of this study was to determine the effect of empagliflozin 10 mg and 25 mg once daily versus placebo for 12 weeks on blood pressure, and glycemic control in type 1 diabetes and hypertension patients. Patients who were included had SBP 130-159 mmHg and DBP 80-99 mmHg, > 18 years of age with BMI < 45kg/m2 and HbA1c >7 to 10 %. Out of the 823 patients, 276 patients received the 10mg empagliflozin, 276 received 25mg empagliflozin, and 271 patients received the placebo. Patients were monitored for their blood pressure at regular intervals for 24 hours before the study and after 12 weeks of treatment.
At week 12, data showed 10mg (SBP -3.44mmHg, DBP -1.36mmHg) and 25mg (SBP -4.16mmHg, DBP -1.72mmHg); both P < 0.001) have a greater reduction in SBP and DBP compared to placebo. At week 12, HbA1c was -0.62 with 10mg empagliflozin and
-0.65% with 25mg empagliflozin compared to placebo.
In conclusion, empagliflozin 10mg and 25mg once daily have shown to be tolerated and clinically significant in the improvement of SBP, DBP, reductions in HbA1c and body weight in patients with type 2 diabetes and hypertension. Adverse events reported in 10mg and 25mg empagliflozin and placebo were mild in intensity.
- Empagliflozin 10mg and 25mg have shown to decrease BP and HbA1c in type 2 diabetes.
- Treatment approach that included control of BP and glycemic significantly reduced the risk of cardiovascular events.
- A significant reduction in cardiovascular events when SBP <150 mmHg and DBP <85 mmHg.
“Diabetes Care.” Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension. N.p., n.d. Web. 13 Oct. 2014